Background Ventricular arrhythmias (VAs) are independent predictors of mortality in survivors of myocardial infarction (MI), and they are more likely to be induced in dilated hearts with increased wall stress. Angiotensin-converting enzyme (ACE) inhibitors have been shown to prevent progressive dilation of the left ventricle after MI.
Background Ventricular arrhythmias (VAs) are independent predictors of mortality in survivors of myocardial infarction (MI), and they are more likely to be induced in dilated hearts with increased wall stress. Angiotensin-converting enzyme (ACE) inhibitors have been shown to prevent progressive dilation of the left ventricle after MI.
Methods and Results The effects of captopril were evaluated in 58 patients with left ventricular (LV) dysfunction after MI. Patients were randomized on day 7 to either placebo or captopril (50 mg daily) in a double-blind parallel study over a period of 6 months. Patients were followed up by means of ambulatory ECG monitoring and echocardiography. There was a significant increase in VA in the placebo group (P<.05) in contrast to a significant decrease in the captopril group (P<.05). As a consequence, there was a significant betweengroup difference after 6 months (P<.05). Furthermore, the number of patients without VA at baseline who presented with this at the completion of the study was 6% in the captopril group versus 38% in the placebo group (P<.05). At baseline as well as at the termination of the study, LV end-diastolic volume index (LVEDVI) and LV end-systolic volume index (LVESVI) were significantly increased among patients with VA (P<.01). On day 180, both myocardial ischemia and an increase in the LVEDVI were independent predictors of VA; however, progressive dilation of the left ventricle was confined to the placebo patients with significant increases in the LVEDVI compared with the captopril group: 17% versus 0%, respectively (P<.01). Furthermore, the duration of ambulatory ST-segment depression was significantly longer in this group compared with the captopril group (P<.01).
Conclusions Dilation of the left ventricle and myocardial ischemia predict VA during both the acute and chronic phases after MI. In post-MI patients with LV dysfunction, captopril has a beneficial effect on both the number of complex VAs as well as the number of patients who develop VA during the chronic phase. This is in all probability mediated through effects on both LV remodeling, LV In addition, load manipulation by captopril as well as enalapril has been shown to reduce the incidence of sudden cardiac death and ventricular tachycardia (VT) in patients with severely reduced LV function.19,20 Captopril also may have an effect on impulse conduction2' and sympathetic tone. 22 The aim of the present study was to examine the relation between LV dilation, LV function, and myocardial ischemia compared with the prevalence and severity of VA in post-MI patients with reduced LV function. The effect of captopril on these relations also was assessed.
have been presented previously. 17 The database comprises patients with an established diagnosis of MI included if they had an LV ejection fraction (EF) <45% on day 5 after MI and were below the age of 70 years.
Patients with a history of congestive heart failure and patients requiring an ACE inhibitor or digoxin were excluded, as were patients with a systolic blood pressure <100 mm Hg, atrial fibrillation, diseases of the heart valves, bundle branch block, heart aneurysm, severe systemic disease, and liver or kidney disease.
The study was carried out in agreement with the Helsinki II declaration and was approved by the regional Scientific Ethical Committee as well as the Danish National Board of Health. Patients gave their consent to participate after both oral and written information.
Study Design
The present study was a randomized, placebo-controlled, double-blind parallel study. Patients were randomized on day 7 to receive a blinded test dose of placebo or captopril 6.25 mg. This was followed by placebo or captopril 12.5 mg BID for a period of 2 weeks. After a clinical control, the daily dose of placebo or captopril was increased to 25 mg BID. This medication was continued for the remainder of the trial period, which lasted 180 days.
Measurements
Echocardiography was carried out according to a standardized protocol on day 5 and repeated on days 30, 90, and 180 after the MI. Patients were examined in the left lateral decubitus position, and echocardiographic recordings were obtained at end expiration during normal breathing; an apical four-chamber view was used. The LV end-diastolic volume was measured at the onset of the QRS complex and the endsystolic volume at the end of the T wave using ECG-triggered recordings. The single-plane area-length method was used for calculation of volumes on the screen of the echocardiograph; the mean of three measurements was used. LV end-diastolic volume index (LVEDVI, mL/m2) and LV end-systolic volume index (LVESVI, mL/m2) were derived using the surface area estimated at each time point. The interobserver coefficient of variation (CV%) was 2% and the intraobserver CV% was 1.2% for repeated measurements of consecutive samples.17
Transmitral flow was obtained from the apical four-chamber view between the mitral leaflets by using pulsed-wave Doppler echocardiography (transducer, 2 mHz; sample length, 2 mm). The ratio between early and atrial peak flow velocities (PE/PA ratio) was calculated using the mean of five measurements.
Twenty-four hours of calibrated ambulatory ECG monitoring using an amplitude-modulated monitor, Reynolds tracker, was carried out on day 6 after MI and repeated on days 30, 90, and 180. Tapes were replayed under visual observation at 60 times the recording speed on a Reynolds pathfinder 3ST connected to a computerized arrhythmia unit, Laserpack. The presence of premature ventricular beats (PVCs) > 10x hoursẁ as noted, as were couplets and VT, defined as three or more PVCs in a row with a rate >10xmin 1.
ST-segment analyses also were performed using the Reynolds ST scope unit. Only horizontal and downsloping STsegment depression of at least 0.1 mV with a duration of 1 minute measured 80 milliseconds after the J-point was considered a sign of ischemia. All episodes of significant ST-segment depression were printed out for visual evaluation before final acceptance.
The intraobserver day-to-day variability was determined from a random sample of 20 Holter tapes. The intraobserver CV% was 1.2% for the detection of couplets per VT, 3.5% for the detection of PVCs, and 4% for the detection of significant ST-segment depressions.
Additional Medication
Treatment with the thrombolytic agent streptokinase as well as oral treatment during days 0 to 5 with low-dose acetylsalicylic acid, (3-blockers, nitrates, calcium antagonists, and diuretics followed the standard of the department. No patient received antiarrhythmic medication other than 3-blockade.
p-Blockers were used in 22 patients in both the placebo and captopril groups at baseline and 21 patients in both groups at the termination of the study.
Statistical Analyses
The baseline data were compared using the x2 test for categorical variables and the unpaired t test for continuous variables. The effects of treatment within and between groups were tested using the Kruskall-Wallis test. The Mantel-Haenzel x2 test was used to calculate rate differences and 95% confidence intervals. CV% was calculated as the relation between the standard deviation and the mean of the observations multiplied by 100%. A value of P<.05 was considered statistically significant.
Results

Captopril vs Placebo
A total of 64 patients were enrolled. Six patients dropped out during the trial period. The reasons for dropout were the following: 2 patients died, 3 patients were subjected to coronary artery bypass grafting, and 1 patient was lost to follow-up. Thus, a total of 58 patients, 29 in each parallel group, completed the trial period, and data presented include only these 58 patients. Baseline clinical and demographic profiles for the randomization groups are listed in Table 1 . No significant differences between groups were noted.
A gradual reduction in the number of couplets per VT from 75 to 15 (P<.05) episodes was observed in the captopril group throughout the trial period. This was in contrast to a gradual increase in the number of couplets per VT from 23 to 118 in the placebo group (P<.05). These changes gave rise to a significant between-group difference at the completion of the study (P<.05). The prevalence of VA did not change significantly either within or between groups during the trial period. However, of 17 patients in the captopril group without VA at baseline, 1 had VA at the completion of the study. This is in contrast to 8 patients with VA out of 21 in the placebo group (P<.05) ( Table 2 ).
Characteristics of Patients With VA
The group with ventricular ectopy at baseline consisted of 5 patients with PVC >10xhours-1 and 18 patients with couplets per VT; 3 patients had both PVC >1Oxhours-1 and couplets per VT; thus, a total of 20 patients had VA at baseline, and the total number of couplets per VT was 98 (Table 2) . Throughout the trial period there was a slight increase in both the prevalence and severity of VA in the total population (Table 2) . VA was present in 23 patients (40%) of the total population at the completion of the study. Six patients had PVC >10 x hours`and 22 had couplets per VT; 5 had both PVC >l0xhours`and couplets per VT, and the total number of couplets per VT was 133 ( Table 2) .
The demographic and clinical profiles of patients with and without VA are presented in Table 3 . There was no significant difference in demographic data. Significant between-group differences were noted regarding clini- (Fig 3) . Moreover, an increase in LVESVI was observed in 29 patients, of whom 14 had VA (Table 4) . Furthermore, the percentage change in LVESVI among patients with VA was 8% versus -5% in patients without VA (P<.01), with the corresponding values being -13% in the captopril group versus + 14% in the placebo group (P<.01) (Fig 3) . Frequent and complex VAs are an independent risk factor for cardiac mortality after MI, and their impact on risk increases when combined with reduced LV function and/or myocardial ischemia.' There is growing evidence that increased myocardial wall stress and ventricular loading play an important role in the genesis of arrhythmias associated with reduced LV function, especially in combination with increased LV volume.12-14 The great majority of VAs in hearts with healed myocardial infarction are due to reentry, with the anatomic substrate being isolated bundles of surviving myocardial fibers within the infarct zone. 23 Several possible mechanisms could underlie this arrhythmogenesis,24 including increased cardiac sympathetic nerve stimulation leading to arrhythmic events and mortality in post-MI patients. 25 Holter monitoring discloses VA in 50% to 80% of post-MI survivors just before hospital discharge.2-4 The varying prevalence reflects differences in definition criteria as well as different durations of Holter monitoring, with the prevalence increasing after longer duration of Holter monitoring. Complex VAs are independent predictors of both sudden and total cardiac death in all of the cited studies.2-4 However, all of these results stem from the prethrombolytic era. Recent reports suggest that thrombolytic therapy markedly reduces the prevalence of VA.26 Furthermore, our study confirms previously reported beneficial acute and long-term effects of , 8-blockade6,7 because the use of p-blockers in the present study was more frequent among patients without VA. The frequent use of streptokinase (82% of patients) and p-blockers (76% of patients) in our patient population may explain the low prevalence of VA during both the acute and follow-up phases.
The need for a long-lasting Holter monitoring has been emphasized because of the considerable day-today variation in ventricular ectopy. 27 The present study shows that VAs are more easily induced in patients with a dilated left ventricle, as demonstrated by the significant difference in LVEDVI throughout the trial period in the VA group. In addition, changes in LV wall stress, as indicated by percent change in LVEDVI during follow-up, were a predictor of VA at the termination of the study. Finally, diastolic dysfunction as reflected by PE/PA ratio also was present in patients with VA. The progressive dilation of the left ventricle observed in the placebo group could have been responsible for the increasing number and severity of VAs observed in this group compared with the captopril group, in which LV dilation was prevented. The fact that VAs were more frequent among patients with Q-wave MI is not surprising because remodeling of the left ventricle is known to be restricted to Q-wave MI survivors.
Myocardial ischemia was a predictor of VA in the present study. The prediction of VA is even more powerful if one combines both increases in LVEDVI and myocardial ischemia. Given the previously demonstrated relation between myocardial remodeling and duration of myocardial ischemia,17 it is foreseeable that captopril had an effect on VA in this post-MI population.
An increase in LVESVI was not a predictor of VA during follow-up in the present study. We cannot explain this. However, there was a considerable betweengroup difference, with a significant reduction in LVESVI in the captopril group, and correspondingly, LVESVI was reduced in patients without VA on day 180 in contrast to an increase in LVESVI in patients who presented with VA on day 180. Thus, part of the effect of captopril could be mediated by a beneficial effect on systolic function. The effect on LVESVI is of particular interest because this variable has been shown to be a powerful predictor of prognosis in post-MI patients.30 It is possible that LVESVI reflects both the extent of dilation as well as systolic function of the left ventricle.
Conclusions
Dilation of the left ventricle and myocardial ischemia predict VA during both the acute and chronic phases after MI. In post-MI patients with LV dysfunction, captopril has a beneficial effect on both the number of complex VAs as well as the number of patients who develop VA during the chronic phase. This is in all probability mediated through effects on LV remodeling, LV function, and myocardial ischemia in patients who are exposed to an increased risk of undergoing progressive dilation of the left ventricle.
